Theraclion Announces First Sale in Egypt and over 100 Leads from German and Italian Congresses

Regulatory News:

THERACLION (Paris:ALTHE) (Alternext, FR0010120402 - ALTHE), a company specialized in leading-edge medical equipment for echotherapy, announces today the first Echopulse® sale in Egypt with AB Care, the local distributor of Theraclion. The system will be installed at EgyHiFu (https://www.facebook.com/egyhifu), a state of the art center in Cairo, specialized in the treatment of abdominal and prostate tumors using HIFU technology.

Khaled Dabees, Assistant Professor of Urology and Managing Director of AB Care declares "We are delighted to confirm our interest in Theraclion’s Echopulse® technology which enables fast, accurate and safe thermal ablation of benign lesions for breast fibroadenoma and benign thyroid nodules. We will now be able to grant access to a vast cohort of patients in Cairo to non-invasive surgical treatment and we look forward to expanded reach in the Middle East.”

Theraclion also announces encouraging outcomes following expanded congress participations in the first half of the year:

• During the German Nuclear Medicine Congress in Hannover on April 22-25^th, two presentations by members of the University of Frankfort in the official scientific program as well as the presence of Theraclion in the industry exhibition caught the attention of the delegates.
• During the Congress of the National Association of Endocrine Surgeons in Naples, Italy on June 4-6^th, thyroid specialists attended live demonstrations of the Echopulse® system.
• Radiologists and other breast specialists from all over Italy visited Theraclion’s booth during the congress of the Italian Senology Society in Verona on June 8-10^th.

Combined these congresses generated over 100 leads. The promotion of the Echopulse® system will continue throughout the month of June, with Theraclion attending the following events:

• The SIFEM Congress, the French Women Imaging Society in Paris on June 11-13^th.
• The Annual Meeting of the Association of Breast Surgery in Bournemouth, UK on June 15^th and 16^th. (In addition to the corporate participation at the latter event, Echopulse investigator Dr. Mirjam Peek has been selected for the poster prize for work confirming the efficacy and safety of cases performed at King's College London, Guy's Hospital, UK.)
• The German Senology Congress in Leipzig, , the final event of this series, held on June 25-27^th, where Theraclion will also participate in the industry exhibition, side by side with German Echopulse® users.

In addition Echopulse® has caught the attention of the general media:

• In Germany the Bayrischer Rundfunk (Bavaria Broadcast) broadcasted a documentary on May 19^th on thermoablative methods, and Echopulse® in particular. NetDoktor, a well-known patient information portal, also reported on the use of Echopulse® for the treatment of thyroid nodules. The Schkeuditzer Bote, the Leipziger Volkszeitung, and the Berliner Kurrier (all local or regional papers in Eastern Germany) published articles on the availability of the Echopulse® procedure in Leipzig.
• In France the blogger community discovered the topic of Echopulse®. Both Carevox.fr and toutpourlesfemmes.com now inform patients on the procedure.
• In Bulgaria, Prof. Kovatcheva, University Hospital of Endocrinology of Sofia, Bulgaria, discussed the advantages of the Echopulse® procedure on Bulgarian National Television (BNT).

"This first sale in Egypt is a very promising step towards further international development”, says David Caumartin, CEO of Theraclion. "Egypt is one of the largest countries in the Middle East & African region and the collaboration with AB CARE is very promising. They are specialized in HIFU technology and very well connected to the healthcare community in the Middle East and in Africa. The return on investment of our congress participation in Europe as well as the recent media attention is encouraging proof of the effectiveness of the strategy we are implementing in Europe.”

About Theraclion:

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.

Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 25 people, 52 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.

Theraclion is listed on Alternext Paris
PEA-PME Eligible
Mnemonic: ALTHE - ISIN Code: FR0010120402

View source version on businesswire.com: http://www.businesswire.com/news/home/20150610006440/en/